About: Beyond Performance Status

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Beyond Performance Status Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Beyond Performance Status
Creator	Wright, J Simcock, R
Source	Elsevier; Medline; PMC
abstract	Oncologists should recognise the need to move beyond the Eastern Cooperative Oncology Group Performance Status (ECOG PS) score. ECOG PS is a longstanding and ubiquitous feature of oncology. It was evolved 40 years ago as an adaption of the 70-year-old Karnofsky performance score. It is short, easily understood and part of the global language of oncology. The wide prevalence of the ECOG PS attests to its proven utility and worth to help triage patient treatment. The ECOG PS is problematic. It is a unidimensional functional score. It is mostly physician assessed, subjective and therefore open to bias. It fails to account for multimorbidity, frailty or cognition. Too often the PS is recorded only once in wilful ignorance of a patient's changing physical state. As modern oncology offers an ever-widening array of therapies that are ‘personalised’ to tumour genotype, modern oncologists must strive to better define patient phenotype. Using a wider range of scoring and assessment tools, oncologists can identify deficits that may be reversed or steps taken to mitigate detrimental effects of treatment. These tools can function well to identify those patients who would benefit from comprehensive assessment. This overview identifies the strengths of ECOG PS but highlights the weaknesses and where these are supported by other measures. A strong recommendation is made here to move to routine use of the Clinical Frailty Score to start to triage patients and most appropriately design treatments and rehabilitation interventions.
has issue date	2020-07-16(xsd:dateTime)
bibo:doi	10.1016/j.clon.2020.06.016
bibo:pmid	32684503
has license	no-cc
sha1sum (hex)	9e19a4c341416edc024f43402736e29e08122d2d
schema:url	https://doi.org/10.1016/j.clon.2020.06.016
resource representing a document's title	Beyond Performance Status
has PubMed Central identifier	PMC7365102
has PubMed identifier	32684503
schema:publication	Clin Oncol (R Coll Radiol)
resource representing a document's body	covid:9e19a4c341416edc024f43402736e29e08122d2d#body_text
is schema:about of	named entity 'Frailty' named entity 'identifies' named entity 'xxx' named entity 'SHORT' named entity 'PART OF' named entity 'TOO OFTEN' named entity 'SCORE' named entity 'FRAILTY' named entity 'SUBJECTIVE' named entity 'IDENTIFY' named entity 'SCORING' named entity 'TO IDENTIFY' named entity 'LANGUAGE' named entity 'PROBLEMATIC' named entity 'AGO' named entity 'UNDERSTOOD' named entity 'identify' named entity 'triage' named entity 'supported' named entity 'tumour' named entity 'modern' named entity 'physical' named entity 'effects' named entity 'measures' named entity 'weaknesses' named entity 'evolved' named entity 'adaption' named entity 'rehabilitation' named entity 'ECOG' named entity 'multimorbidity' named entity 'cognition' named entity 'oncology' named entity 'recognise' named entity 'KPS' named entity 'functional status' named entity 'CGA' named entity 'polypharmacy' named entity 'toxicity' named entity 'Cancer Drug' named entity 'ECOG' named entity 'shared decision making' named entity 'secondary care' named entity 'Performance Status' named entity 'immunotherapy' named entity 'March 2020' named entity 'Palliative' named entity 'screening tool' named entity 'cancer immunotherapy' named entity 'ECOG' named entity 'lung cancer' named entity 'Performance Status' named entity 'Karnofsky' named entity 'pneumonia' named entity 'advanced stage' named entity 'Palliative' named entity 'CGA' named entity 'ECOG' named entity 'Eastern Cooperative Oncology Group' named entity 'Comprehensive Geriatric Assessment' named entity 'ECOG' named entity 'oncology' named entity 'Dihydropyrimidine dehydrogenase deficiency' named entity 'oncologist' named entity 'triage' named entity 'ECOG' named entity 'palliative' named entity 'metastasis' named entity 'CGA' named entity 'clinical trial' named entity 'ECOG' named entity 'palliative care' named entity 'CGA' named entity 'elderly care' named entity 'functional status' named entity 'tumour' named entity 'oncologists' named entity 'diagnostic medicine' named entity 'personalised medicine' named entity 'morbidity' named entity 'KPS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software